AI Aids Risk Prediction Classification for Prostate Cancer
WEDNESDAY, Nov. 6, 2024 -- Artificial intelligence (AI)-based risk classification improves prognostication with localized prostate cancer, according to a study published online Oct. 24 in JCO Precision Oncology.
Jonathan David Tward, M.D., Ph.D., from the University of Utah in Salt Lake City, and colleagues developed a clinically usable risk grouping system using multimodal AI (MMAI) models to risk-stratify localized prostate cancer. The analysis included 9,787 patients with localized prostate cancer from eight phase 3 trials treated with radiation therapy, androgen deprivation therapy, and/or chemotherapy followed for a median 7.9 years.
The researchers found that according to National Comprehensive Cancer Network (NCCN) risk categories, 30.4 percent of patients were low-risk, 25.5 percent intermediate-risk, and 44.1 percent high-risk. Based on MMAI risk classification, 43.5 percent of patients were low-risk, 34.6 percent intermediate-risk, and 21.8 percent high-risk, yielding reclassification of 1,039 patients (42.0 percent). The 10-year metastasis risks were comparable despite the MMAI low-risk group being larger than the NCCN low-risk group (1.7 percent for NCCN versus 3.2 percent for MMAI). For NCCN high-risk patients, the overall 10-year metastasis risk was 16.6 percent, with MMAI further stratifying this group into low-, intermediate-, and high-risk, with metastasis rates of 3.4, 8.2, and 26.3 percent, respectively.
"This approach aims to prevent both overtreatment and undertreatment in localized prostate cancer, facilitating shared decision-making," the authors write.
Several authors disclosed ties to pharmaceutical and biotechnology companies.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Higher Tattoo Exposure Linked to Reduced Melanoma Risk
MONDAY, Sept. 29, 2025 -- Higher tattoo exposure may be associated with reduced melanoma risk, according to a study published online Aug. 21 in the Journal of the National Cancer...
Antithymocyte Globulin Cuts Loss of β-Cell Function in Type 1 Diabetes
MONDAY, Sept. 29, 2025 -- Antithymocyte globulin (ATG) 2.5 and 0.5 mg/kg reduces loss of β-cell function in young people with recent-onset type 1 diabetes, according to a...
Loss of Therapeutic Benefit Seen After Stopping Baricitinib in Type 1 Diabetes
MONDAY, Sept. 29, 2025 -- Two-year follow-up shows a loss of therapeutic benefit when baricitinib treatment is stopped in type 1 diabetes (T1D), according to a study presented at...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.